Basmisanil clinical trials
Also written RG1662 and RO5186582.
How each study uses basmisanil is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the basmisanil studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2014 (3)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 2 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 1 |
| 2022 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 0
Hoffmann-La Roche (12) · Newleos Therapeutics, Inc. (1)
Studies
Open first, then newest update. How each study uses basmisanil is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- A Phase II Study of Basmisanil in Children and Adolescents With Dup15q SyndromeNot yet recruitingPhase 2Newleos Therapeutics, Inc.NCT07846215Written as Basmisanil
- A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q SyndromeTerminatedPhase 2Hoffmann-La RocheNCT05307679Written as Basmisanil
- A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With AntipsychoticsCompletedPhase 2Hoffmann-La RocheNCT02953639Written as Basmisanil
- A Study to Evaluate the Safety and Efficacy of Basmisanil in Adults With Severe Motor Impairment Following an Ischemic StrokeTerminatedPhase 2Hoffmann-La RocheNCT02928393Written as Basmisanil
- A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS)CompletedPhase 2Hoffmann-La RocheNCT02024789Written as RG1662
- A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of AgeTerminatedPhase 2Hoffmann-La RocheNCT02484703Written as RO5186582
- Basmisanil Positron Emission Tomography Study in Japanese VolunteersCompletedPhase 1Hoffmann-La RocheNCT02534207Written as Basmisanil
- Comparative Bioavailability Study of Film-coated Tablet and Granule Formulations of RG1662CompletedPhase 1Hoffmann-La RocheNCT02194244Written as RG1662 granules
- A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male VolunteersCompletedPhase 1Hoffmann-La RocheNCT01684891Written as RG1662
- A Study of RO5186582 Treatment on Cytochrome P450 (CYP) 3A4 Activity in Healthy ParticipantsCompletedPhase 1Hoffmann-La RocheNCT02254759Written as RO5186582
- A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RG1662 in Healthy SubjectsCompletedPhase 1Hoffmann-La RocheNCT02470832Written as RG1662
- A Molecular and Functional Brain Imaging Study in Individuals With Down Syndrome and Healthy Controls Following Single Dose RG1662CompletedPhase 1Hoffmann-La RocheNCT01667367Written as RG1662
- A Study of RG1662 in Individuals With Down SyndromeCompletedPhase 1Hoffmann-La RocheNCT01436955Written as RG1662
Given beside what is tested · 1 — basmisanil is usual care or a partner of the new treatment
Codes
What other systems call basmisanil · ClinicalTrials.gg INT001739
- MeSH (NLM) C000720034basmisanilOne source NLM
- UNII (FDA) 788PET5SUABASMISANILConfirmed FDA, NLM, Wikidata
- Wikidata Q20707932basmisanilConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C167009BasmisanilOne source FDA
- DrugBank DB11877One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720034 | basmisanil | One source NLM |
| UNII (FDA) | 788PET5SUA | BASMISANIL | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q20707932 | basmisanil | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C167009 | Basmisanil | One source FDA |
| DrugBank | DB11877 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.